Thermo Fisher Scientific (TMO) EBT Margin (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported EBT Margin for 18 consecutive years, with 16.04% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT Margin rose 30.0% year-over-year to 16.04%; the trailing twelve-month figure through Jun 2026 stood at 16.48% (up 25.0% YoY), and the FY2025 full-year result was 16.4%, down 1.0% from the prior year.
• EBT Margin improved to 16.04% in Q2 2026 per TMO's latest filing, from 15.76% in the prior quarter.
• Across five years, EBT Margin topped out at 21.49% in Q2 2022 and bottomed at 12.73% in Q2 2023.
• Historically, EBT Margin has averaged 16.17% across 5 years, with a median of 16.01% in 2023.
• The sharpest annual moves came in 2023 and 2024: EBT Margin tumbled 877 bps in 2023, then jumped 336 bps in 2024.
• Over 5 years, EBT Margin stood at 15.52% in 2022, then gained by 3 bps to 15.98% in 2023, then climbed by 7 bps to 17.03% in 2024, then advanced by 3 bps to 17.63% in 2025, then slipped by 9 bps to 16.04% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 16.04%, 15.76%, and 17.63% for Q2 2026, Q1 2026, and Q4 2025 respectively.